Clinicians, including hematologists, are more frequently encountering transgender individuals in practice; however, most lack training on the management and complications of transgender medicine. Hormonal therapy forms the backbone of medical interventions for patients undergoing gender transition. While supplementing an individual's intrinsic sex hormone is associated with a variety of hematologic complications including increased rates of venous thrombosis, cardiovascular events, erthyrocytosis, and malignancy, the risks of supplementing with opposing sex hormones are not well understood. Data on the hematologic complications of these therapies are accumulating but remain limited, and clinicians have little experience with their management. This review highlights the current interventions available in transgender medicine and related potential hematologic complications, and it suggests simple, evidence-based management going forward.
Introduction
Transgender individuals have a gender identity that does not align with their assigned sex at birth. Although recent epidemiologic studies are lacking, older data suggest at least 700,000 people identify as transgender in the United States alone [1] . Both medical interventions as well as gender reassignment surgeries are available to individuals transitioning from male to female (MTF) or female to male (FTM). However, there remains a lack of education on the part of providers on the use of these interventions, as well as a lack of prospective data on the efficacy, and side effect profile they entail [2, 3] . For multiple reasons, the health needs of transgender individuals may often go unmet [4] .
Hormonal therapy forms the backbone of medical interventions for patients undergoing gender transition [2] . Supplementing an individual's intrinsic sex hormonesis associated with a variety of hematologic complications, including higher rates of venous thrombosis, cardiovascular events, erythrocytosis, and malignancy. However, the risks of supplementing with opposing sex hormones are not well understood. The thrombotic complications of transgender medicine, in particular, can lead to morbidity in individuals transitioning genders. With proper management and forethought, many of these complications can be prevented or abated. In this review we outline the current interventions available in transgender medicine and discuss the related potential hematologic complications.
Treatment Options for Transgender Women(Male-to-Female, or MTF)
Individuals undergoing gender transition from male to female have multiple medical options, including hormonal therapy and gender affirming surgery; these should be guided by a clinician experienced with transgender medicine. The goal of hormonal therapy is the development of secondary female sex characteristics, which include breast growth, reduction in facial and body hair, redistribution of body fat, reduced muscle mass, and testicular atrophy [5] . Many pubertal changes such as vocal cord development and voice deepening are not reversible with hormonal therapy. Both the World Professional Association for Transgender Health (WPATH) and the Endocrine Society provide guidelines on hormonal therapy available for transgender women (MTF), which includes the use of both antiandrogen and estrogen supplementation [6, 7] . (Supporting Information Table I ) Transgender women who retain their testes may use both antiandrogens and estrogens, with the goal of reducing testosterone to a range of 30-100 ng dl 21 without obtaining an excessive level of estradiol (goal is <20 ng dl
21
) [2] . Generally, transition is stepwise, with a period of time living as a transgender woman on hormonal therapy preceding any gender affirming surgery. If orchiectomy is undertaken, hormonal therapy must still be continued to prevent vasomotor symptoms and osteoporosis, although antiandrogen therapy can be decreased or stopped [8] .
Thrombotic risk in cisgender women receiving hormone replacement therapy
While data on the use and thrombotic complications of hormonal therapy in men transitioning to women is limited, thrombotic complications have been well-described in women with the use of estrogen supplementation. Estrogen causes several procoagulant shifts in the hemostatic system, including increased levels of factors II, VII, VIII, X, and fibrinogen, as well as decreased levels of antithrombin, protein S and the development of activated protein C resistance [9, 10] . A reasonable biologic correlate to the hormone supplementation transgender women receive is menopausal hormone replacement therapy(HRT), which generally consists of combined estrogen and progesterone in women who retain their uterus (due to the protective effects of progesterone against uterine malignancy) and estrogen monotherapy in women who have undergone hysterectomy. While true that the type, route, and dose of estrogen as well as the presence of progesterone affects the thrombotic risk, pooled analyses from multiple prospective and randomized controlled trials of HRTas a whole have demonstrated up to a fourfold increase in rates of venous thrombosis within the first year of therapy [11] . (Supporting Information Table II) These risks should be taken into context with the incidence of first venous thrombosis in the general population of women; this increases with age from 0.72 per 1000 per year in women over 50 years old, to 3.84 per 1000 per year in women over 80 [12] . Individuals with inherent risks for thrombosis including obesity, active tobacco use, a prior history of thrombosis, and those with a thrombophilia are at even higher risks while taking oral estrogen [11, 13] . Women with a previous history of thrombosis who are placed on hormone replacement have up to a 10% annual incidence of recurrent thrombosis, leading some to suggest that a prior history of thrombosis is a contraindication to HRT [13] . The risks of thrombosis in women using transdermal estrogen appear to be less than with oral estrogen. Meta-analyses suggest that transdermal estrogens may carry minimal or no thrombotic risk (relative risk 1.0 (95% CI 0.9-1.1), even in women with a prior history of thrombosis. Transdermal estrogens have minimal effects on hemostatic variables such as thrombin generation and activated protein C resistance [14] . This has led some authors to suggest transdermal estrogen as the first-line agent in women with thrombotic risk factors who desire HRT [11, 14] .
Thrombotic risk in transgender women receiving hormonal therapy
While much epidemiologic data is available to guide decisions regarding thrombotic risk in women receiving HRT, there are no prospective trials available on the risks of venous thrombosis in genetically male individuals taking oral or transdermal estrogen. Some insights have been gained from studies on men receiving hormonal deprivation or estrogen therapy for prostate cancer. Observational data of men receiving androgen deprivation therapy for prostate cancer with gonadotropin-releasing hormone agonists (GnRH analogs) or bilateral orchiectomy suggest these patients do have higher rates of thrombosis after controlling for other risk factors [15] . There is also data examining the use of high dose estrogen in men with prostate cancer which show that the thrombosis risk-both arterial and venous-was substantial. However, these patients were older, often had other thrombotic risk factors, and higher estrogen doses were used than are typically used in transgender women [16] .
While good quality data are admittedly lacking in the transgender setting, there are several retrospective series which have evaluated the risks of thrombosis in transgender women (MTF). (Table I ) Although findings vary due to population characteristics and type of estrogen used, in general the results suggest that transgender women have a higher rate of venous thromboembolism with certain estrogens. The rate is highest with oral estrogen supplementation, particularly ethinyl estradiol, and lowest with transdermal estrogen and estradiol valerate. Thrombosis is most likely to occur in the first year after starting estrogen supplementation; this is consistent with data of women taking estrogen-containing oral contraception [23] . Additionally, transgender women who smoke appear to have a higher risk for venous thrombosis [17, 18] .
Managing hormonal therapy in transgender women at high risk for thrombosis
The decision to start hormonal therapy in transgender women with a prior history of thrombosis is a challenging one. For patients with a history of venous thrombosis, the use of transdermal estrogen appears to be less thrombotic, and should be the first choice for therapy. This is confirmed by studies in men treated for prostate cancer which showed that surrogate markers of thrombotic risk-including factor VII and protein S levels and activated protein C resistance-did not change with the use of transdermal estrogen [28] . Several studies of women receiving hormone replacement therapy suggest a dose-response relationship between HRT use and venous thrombosis incidence [29] . Although data are insufficient to draw the same conclusion in transgender women, one can extrapolate that lower doses of hormonal therapy may result in decreased risk. This strategy may be considered in transgender women with high baseline thrombotic risk. In women planning to start HRT, professional societies recommend against routine screening for thrombophilia, which seems appropriate for transgender women as well [30] . Contradictory to data in women receiving HRT, a small retrospective series suggested that pre-existing thrombophilia did not increase the risk of thrombosis in transgender women, although the overall data suggest that transdermal estrogen should be considered in those with a known thrombophilia [14] . Currently, there is no role for thrombophilia screening in asymptomatic individuals transitioning genders. Likewise, data are lacking to suggest any role for thromboprophylaxis with either aspirin or anticoagulation. Although aspirin has shown some benefit in secondary venous thromboembolism (VTE) prophylaxis [31] , in general, data on any benefit it offers in combination with hormone replacement in women are conflicting, with some studies suggesting a mild VTE risk reduction [32] , and others suggesting none [33] . Currently there is insufficient evidence to routinely use aspirin prophylaxis in transgender women, even if they are at increased risk for thrombosis. No data exist on the use of prophylactic anticoagulation in individuals who are at high risk for thrombosis. Currently we would recommend against the routine use of these agents in individuals without another indication for aspirin or prophylactic anticoagulation. 
Managing thrombosis in transgender women on hormonal therapy
Unfortunately, there are no current guidelines on the management or prevention of thrombosis in transgender women. There is, however, good prospective data in women who develop thrombotic complications on estrogen to suggest that therapeutic anticoagulation lowers the rate of recurrent thrombosis and that estrogen therapy can be continued safely as long as the woman remains anticoagulated [34] . However, the risk of recurrent thrombosis is substantial if estrogen is continued after anticoagulation is stopped. Until more studies of transgender patients are done, it is reasonable to extrapolate this data to say that transgender women may have a similarly low rate of recurrent thrombosis if maintained on anticoagulation while on estrogen therapy.
Because for many individuals continuation of estrogen is essential for transitioning genders, there are several options for those who develop thrombosis while on hormonal therapy. Patients who had thrombosis on oral estrogens would likely have a reduction in risk of recurrence by changing to transdermal estrogen therapy. While data suggest a lower rate of thrombosis with transdermal estrogen, rates may still be increased, and the decision to stop anticoagulation in individuals transitioned to transdermal estrogen is a complex one which cannot be safely answered by the current data. Given this, we would recommend continuing anticoagulation in transgender woman who develop a thrombosis on hormonal therapy and are switched to transdermal estrogen, if there are no contraindications. Individuals who develop thrombosis while on transdermal estrogen should definitely be continued on therapeutic anticoagulation indefinitely while on estrogen.
Cardiovascular effects of hormonal therapy in cisgender and transgender women
The cardiovascular effects of HRT are less straightforward. While initially considered cardioprotective in postmenopausal women, large pooled analyses have failed to find significant differences in coronary events, and actually suggest an increased risk of stroke in women taking HRT [35] . (Supporting Information Table III) Retrospective evaluation in transgender women is difficult to interpret without matched controls; however, authors suggest that the rates of myocardial infarction are not lower in transgender women as compared to other genetic males who are not on estrogen, and the rates of stroke may be increased, similar to postmenopausal women [17, 18, 35] . Given the uncertainty, it would be prudent to ensure other cardiovascular risk factors -such as smoking, dyslipidemia, and hypertension-are well controlled.
Preventing postoperative thrombosis in transgender women on hormonal therapy
Postoperative venous thrombosis does occur in transgender women who undergo elective surgery, including gender affirming surgery [23] , leading some authors to suggest holding hormonal therapy for 2 weeks prior to elective surgery and resuming once mobility is regained [18, 36] . No prospective data exists to confirm the benefit of this recommendation, although similar recommendations have been suggested for women receiving postmenopausal hormone replacement therapy [37] . Guidelines regarding women receiving HRT are varied; while some suggest holding HRT prior to surgery, others are equivocal or stress only pharmacologic thromboprophylaxis [38] . Given the lack of data and lack of risk with holding hormonal therapy in transgender women, this 2-week recommendation seems prudent. Standard postoperative thromboprophylaxis is strongly encouraged during hospitalization.
The key points in managing thrombotic risk in transgender women undergoing transition are summarized in Table II .
Treatment Options for Transgender Men (Female-to-Male, or FTM)
Transgender men use supplemental testosterone to promote the development of male secondary sex characteristics including male pattern hair growth, muscle development, and the cessation of uterine bleeding [8] . The Endocrine Society offers recommendations on the use of testosterone for transgender men undergoing transition (FTM) [6] (Supporting Information Table IV) . Menses may continue for several months in transgender men and can be managed with increased doses of testosterone, medroxyprogesterone, endometrial ablation, or GnRH analogs. These interventions can also be used prior to testosterone supplementation to decrease endogenous estrogen levels. As with transgender women, transgender men generally live for a period of time on hormonal therapy before undergoing gender affirming surgery.
Thrombotic risks in cisgender and transgender men receiving hormonal therapy
Unlike exogenous estrogen, supplemental testosterone has not been shown to impact rates of venous thromboembolism. Although some small studies initially suggested testosterone supplementation in men may increase the risk of thrombosis [39, 40] , large retrospective cohort studies of men prescribed testosterone have not demonstrated increased rates of venous thrombosis by any route of administration including topical, transdermal, or injection [41] . Recent large prospective studies have failed to show increased rates of cardiovascular disease in men taking supplemental testosterone, although the sample sizes have been too small to exclude other than a large increase in risk [42] . Data on the risk of venous thrombosis in women receiving testosterone are limited to case reports [39] and retrospective observational series which show no increase in the risk of thrombosis or cardiac events with testosterone use in transgender men (Supporting Information Table V) . Low-dose testosterone therapy has been studied in women in multiple prospective controlled trials as therapy for low libido [43] . In general, as suggested in men, in women an inverse relationship has been observed between testosterone use and cardiovascular risk [44] . Secondary erythrocytosis in transgender menrecieving hormonal therapy
The most commonly reported adverse event in men taking testosterone supplementation is erythrocytosis [45] , although it is unclear what risks, if any, are associated with this [46] . While erythrocytosis has been clearly linked to thrombosis in myeloproliferative neoplasms, there is not compelling data that secondary erythrocytosis leads to increased thrombotic risk, and no data specific to testosterone supplementation, leading authors to admit that any association is inconclusive [47, 48] . Meta-analysis of placebo controlled trials suggests intramuscular administration and higher doses of testosterone lead to greater increases in red cell indices [49] . There also appears to be a dose-response effect [50] . Although injectable testosterone has been suggested to have a greater risk of erythrocytosis as compared to other means of administration, even transdermal testosterone may cause this effect [46] . Currently, the Endocrine Society suggests discontinuation of hormonal therapy in men receiving testosterone for androgen deficiency who have hematocrit levels over 0.54 g l 21 [51] . Other options for transgender men who develop erythrocytosis while taking testosterone include reducing the dose of intramuscular testosterone or switching to transdermal testosterone formulations, which may decrease the risk or degree of erythrocytosis, although direct data comparing modes of administration, or evaluating switching therapy for erythrocytosis is lacking. Practitioners often phlebotomize patients with secondary erythrocytosis, a practice extrapolated from data in patients with myeloproliferative neoplasms which clearly show a risk reduction in the rate of thrombotic events [52] . However, there is no compelling data that phlebotomy reduces the risk of thrombosis in secondary erythrocytosis. Lastly, although randomized data suggest that aspirin decreases the thrombotic rate in individuals with myeloproliferative neoplasms [53] , there is no data to guide its use in secondary erythrocytosis. Observational data suggest that secondary erythrocytosis may not carry an increased thrombotic risk, although more definitive studies are sorely lacking [54] .
The key points in managing thrombotic risk in transgender men undergoing transition are summarized in Table III .
Conclusion
Transgender women (MTF) may have higher rates of venous thromboembolic disease with certain preparations of estrogen. This risk can be mitigated by clinician education and efforts to minimize other thrombotic risks. Transgender medicine is an evolving field, with more data being accrued as more individuals openly seek medical care during gender transition. Despite the data examined in this review, large epidemiologic studies are lacking on the true thrombotic risks in individuals undergoing gender transition. To date, most data on risk are extrapolated from same sex hormone exposure or small retrospective studies investigating opposite sex hormone exposure. Large prospective studies evaluating the complications involved in transgender men and women undergoing transition are imperative. 
